Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Chinol

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Nuclear Medicine Communications|October 21, 1999
Radiation protection in radioguided surgery of breast cancerM Cremonesi, M Ferrari, E Sacco, et al.
European Journal of Nuclear Medicine|August 7, 1999
Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOCM Cremonesi, M Ferrari, S Zoboli, et al.
British Journal of Cancer|July 31, 1998
Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicityM Chinol, P Casalini, M Maggiolo, et al.
European Journal of Nuclear Medicine|April 13, 1999
Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotinG Paganelli, C Grana, M Chinol, et al.
European Journal of Nuclear Medicine|May 19, 2001
Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotideG Paganelli, S Zoboli, M Cremonesi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 1, 1993
Chemistry and biological behavior of samarium-153 and rhenium-186-labeled hydroxyapatite particles: potential radiopharmaceuticals for radiation synovectomyM Chinol, S Vallabhajosula, S J Goldsmith, et al.
British Journal of Cancer|April 3, 2003
Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT)R De Santis, A M Anastasi, V D'Alessio, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Nuclear Medicine Communications|October 21, 1999
Radiation protection in radioguided surgery of breast cancerM Cremonesi, M Ferrari, E Sacco, et al.
European Journal of Nuclear Medicine|August 7, 1999
Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOCM Cremonesi, M Ferrari, S Zoboli, et al.
British Journal of Cancer|July 31, 1998
Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicityM Chinol, P Casalini, M Maggiolo, et al.
European Journal of Nuclear Medicine|April 13, 1999
Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotinG Paganelli, C Grana, M Chinol, et al.
European Journal of Nuclear Medicine|May 19, 2001
Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotideG Paganelli, S Zoboli, M Cremonesi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 1, 1993
Chemistry and biological behavior of samarium-153 and rhenium-186-labeled hydroxyapatite particles: potential radiopharmaceuticals for radiation synovectomyM Chinol, S Vallabhajosula, S J Goldsmith, et al.
British Journal of Cancer|April 3, 2003
Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT)R De Santis, A M Anastasi, V D'Alessio, et al.
Pageof 5